Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: A pilot study

Clinical and Experimental Allergy

Volumn 37, Issue 9, 2007, Pages 1277-1285

  Bussmann, C ^a   Maintz, L ^a   Hart, J ^a   Allam, J P ^a   Vrtala, S ^b   Chen, K W ^b   Bieber, T ^f   Thomas, W R ^c   Valenta, R ^b   Zuberbier, T ^d   Sager, A ^e   Novak, N ^a,f  

^a UNIVERSITY OF BONN   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c University   (Australia)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e LETI Pharma GmbH   (Germany)

^f INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Allergy; Atopic dermatitis; House dust mite; Specific immunotherapy

Indexed keywords

CHEMOKINE; GAMMA INTERFERON; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 16; INTERLEUKIN 4; PROTEIN CCL22; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; MALE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; ALLERGENS; ANIMALS; CHEMOKINES; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DESENSITIZATION, IMMUNOLOGIC; DUST; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; INTERLEUKINS; MALE; MIDDLE AGED; MITES; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34548501796     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2007.02783.x     Document Type: Article

References (40)

1. Novak N, Bieber T. The role of dendritic cell subtypes in the pathophysiology of atopic dermatitis. J Am Acad Dermatol 2005 53 : S171 6.
2. Homey B, Steinhoff M, Ruzicka T, Leung DY. Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol 2006 118 : 178 89.
3. Novak N, Allam P, Geiger E, Bieber T. Characterization of monocyte subtypes in the allergic form of atopic eczema/dermatitis syndrome. Allergy 2002 57 : 931 5.
4. Imai T, Nagira M, Takagi S et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol 1999 11 : 81 8.
5. Laberge S, Ghaffar O, Boguniewicz M, Center DM, Leung DY, Hamid Q. Association of increased CD4+T-cell infiltration with increased IL-16 gene expression in atopic dermatitis. J Allergy Clin Immunol 1998 102 : 645 50.
6. Belloni FA, Tonin E, Pigozzi B, Romano I, Michelotto G, Alaibac M. IL-16 serum level in children with atopic dermatitis. Int J Immunopathol Pharmacol 2006 19 : 841 5.
7. Campbell JJ, O'Connell DJ, Wurbel MA. Cutting edge: Chemokine receptor CCR4 is necessary for antigen-driven cutaneous accumulation of CD4T cells under physiological conditions. J Immunol 2007 178 : 3358 62.
8. Angelova-Fischer I, Hipler UC, Bauer A et al. Significance of interleukin-16, macrophage-derived chemokine, eosinophil cationic protein and soluble E-selectin in reflecting disease activity of atopic dermatitis-from laboratory parameters to clinical scores. Br J Dermatol 2006 154 : 1112 7.
9. Jahnz-Rozyk K, Targowski T, Paluchowska E, Owczarek W, Kucharczyk A. Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis. Allergy 2005 60 : 685 8.
10. Tupker RA, De Monchy JG, Coenraads PJ, Homan A, van der Meer JB. Induction of atopic dermatitis by inhalation of house dust mite. J Allergy Clin Immunol 1996 97 : 1064 70.
11. van den BL, van KL, de Vries MP, Jansen M, Cloosterman S, van Schayck CP. Clinical effectiveness of a mite allergen-impermeable bed-covering system in asthmatic mite-sensitive patients. J Allergy Clin Immunol 2004 114 : 858 62.
12. Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet 1996 347 : 15 8.
13. Oosting AJ, de Bruin-Weller MS, Terreehorst I et al. Effect of mattress encasings on atopic dermatitis outcome measures in a double-blind, placebo-controlled study: the Dutch mite avoidance study. J Allergy Clin Immunol 2002 110 : 500 6.
14. Terreehorst I, Hak E, Oosting AJ et al. Evaluation of impermeable covers for bedding in patients with allergic rhinitis 1. N Engl J Med 2003 349 : 237 46.
15. Gutgesell C, Heise S, Seubert S et al. Double-blind placebo-controlled house dust mite control measures in adult patients with atopic dermatitis. Br J Dermatol 2001 145 : 70 4.
16. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy 1. J Allergy Clin Immunol 2004 113 : 1025 34.
17. Verhagen J, Taylor A, Blaser K, Akdis M, Akdis CA. T regulatory cells in allergen-specific immunotherapy 1. Int Rev Immunol 2005 24 : 533 48.
18. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006 6 : 761 71.
19. Tarzi M, Klunker S, Texier C et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006 36 : 465 74.
20. Ohashi Y, Nakai Y, Tanaka A et al. Risk factors for adverse sytemic reactions occurring during immunotherapy with standardized Dermatophagoides farinae extracts. Acta otolaryngol 1998 538 (Suppl.) : 113 7.
21. Bussmann C, Bockenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol 2006 118 : 1292 8.
22. Hanifin JM. Diagnostic criteria for atopic dermatitis: consider the context 1. Arch Dermatol 1999 135 : 1551.
23. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1993 186 : 23 31.
24. Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997 195 : 10 9.
25. Mothes N, Heinzkill M, Drachenberg KJ et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003 33 : 1198 208.
26. Vrtala S, Grote M, Duchene M et al. Properties of tree and grass pollen allergens: reinvestigation of the linkage between solubility and allergenicity. Int Arch Allergy Immunol 1993 102 : 160 9.
27. Hales BJ, Hazell LA, Smith W, Thomas WR. Genetic variation of Der p 2 allergens: effects on T cell responses and immunoglobulin E binding. Clin Exp Allergy 2002 32 : 1461 7.
28. Lund L, Henmar H, Wurtzen PA, Lund G, Hjortskov N, Larsen JN. Comparison of allergenicity and immunogenicity of an intact allergen vaccine and commercially available allergoid products for birch pollen immunotherapy. Clin Exp Allergy 2007 37 : 564 71.
29. Patterson R, Suszko IM, McIntire FC. Polymerized ragweed antigen E. I. preparation and immunologic studies. J Immunol 1973 110 : 1402 12.
30. Patterson R, Suszko IM, Pruzansky JJ, Zeiss CR. Polymerized ragweed antigen e. ii. in vivo elimination studies and reactivity with IgE antibody systems. J Immunol 1973 110 : 1413 8.
31. Sachs DH, Winn HJ. The use of glutaraldehyde as a coupling agent for ribonuclease and bovine serum albumin. Immunochemistry 1970 7 : 581 5.
32. Casanovas M, Sastre J, Fernandez-Nieto M, Lluch M, Carnes J, Fernandez-Caldas E. Double-blind study of tolerability and antibody production of unmodified and chemically modified allergen vaccines of Phleum pratense. Clin Exp Allergy 2005 35 : 1377 83.
33. Aalberse RC, van der GR, van LJ. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 1983 130 : 722 6.
34. Einarsson R, Dreborg S, Hammarstrom L, Lofkvist T, Smith CI, Svensson G. Monitoring of mite Dermatophagoides farinae allergen-specific IgG and IgG subclass distribution in patients on immunotherapy. Allergy 1992 47 : 76 82.
35. Pacor ML, Biasi D, Maleknia T. The efficacy of long-term specific immunotherapy for Dermatophagoides pteronyssinus in patients with atopic dermatitis. Recenti Prog Med 1994 85 : 273 7.
36. Seidenari S, Mosca M, Taglietti M, Manco S, Nume G. Specific hyposensitization in atopic dermatitis 1. Dermatologica 1986 172 : 229.
37. Ring J. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol 1982 107 : 597 602.
38. Trofimowicz A, Rzepecka E, Hofman J. Clinical effects of specific immunotheraphy in children with atopic dermatitis 1. Rocz Akad Med Bialymst 1995 40 : 414 22.
39. Werfel T, Breuer K, Rueff F et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study 2. Allergy 2006 61 : 202 5.
40. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema 2. Clin Exp Allergy 1992 22 : 440 6.